Actively Recruiting
Autoimmune Blistering Diseases Study
Led by University of Pennsylvania · Updated on 2026-03-30
150
Participants Needed
3
Research Sites
717 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
CONDITIONS
Official Title
Autoimmune Blistering Diseases Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females aged 18 years or older
- Diagnosed with pemphigus vulgaris, pemphigus foliaceus, or bullous pemphigoid
- Able to provide informed consent
You will not qualify if you...
- Patients younger than 18 years
- Patients without pemphigus or pemphigoid diseases
- Penn employees
- Penn students
- Persons with cognitive impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Hospital of the University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
2
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
3
University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
V
Victoria P Werth, MD
CONTACT
J
Joyce Okawa, RN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here